68.59
-0.07 (-0.10%)
| Penutupan Terdahulu | 68.66 |
| Jumlah Dagangan | 23,876 |
| Harga / Jualan (P/S) | 110.67 |
| Harga / Buku (P/B) | 4.63 |
| Julat 52 Minggu |
| Margin Keuntungan | -107.77% |
| Margin Operasi (TTM) | -879.63% |
| EPS Cair (TTM) | -4.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 121.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.84% |
| Nisbah Semasa (MRQ) | 5.12 |
| Aliran Tunai Operasi (OCF TTM) | -13.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -9.91 M |
| Pulangan Atas Aset (ROA TTM) | -26.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Sol-Gel Technologies Ltd. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 1.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| Purata | 0.44 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 70.00% |
| % Dimiliki oleh Institusi | 24.29% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Navellier & Associates Inc | 30 Jun 2026 | 5,785 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |